Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Show more

7 Golda Meir Street, Ness Ziona, 7403650, Israel

https://www.sol-gel.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

272M

52 Wk Range

$8.03 - $97.97

Previous Close

$78.08

Open

$77.68

Volume

40,555

Day Range

$77.68 - $86.90

Enterprise Value

220M

Cash

52.83M

Avg Qtr Burn

N/A

Insider Ownership

59.70%

Institutional Own.

37.37%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EPSOLAY® (benzoyl peroxide) Cream Details Papulopustular Rosacea	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1% Details Acne Vulgaris	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SGT-610 (Patidegib) Details Gorlin Syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Patidegib (SGT-610) (Hedgehog Inhibitor) Details High-Frequency Basal Cell Carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SGT-210 (Erlotinib) Details Darier Disease, Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.